CDMO Avid Bioservices Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CDMO

Price (delayed)

$17.8

Market cap

$1.11B

P/E Ratio

9.37

Dividend/share

N/A

EPS

$1.9

Enterprise value

$1.23B

Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a ...

Highlights
CDMO's revenue is up by 21% year-on-year and by 4.9% since the previous quarter
Avid Bioservices's equity has increased by 2.3% QoQ
CDMO's gross profit is down by 20% year-on-year but it is up by 2.5% since the previous quarter
Avid Bioservices's quick ratio has plunged by 63% YoY and by 28% from the previous quarter
Avid Bioservices's gross margin has decreased by 34% YoY and by 2.3% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://avidbio.com
Peers: NTRA NEOG MYGN

Key stats

What are the main financial stats of CDMO
Market
Shares outstanding
62.55M
Market cap
$1.11B
Enterprise value
$1.23B
Valuations
Price to earnings (P/E)
9.37
Price to book (P/B)
5.98
Price to sales (P/S)
7.89
EV/EBIT
271.88
EV/EBITDA
109.34
EV/Sales
8.77
Earnings
Revenue
$140.69M
EBIT
$4.54M
EBITDA
$11.28M
Free cash flow
-$92.4M
Per share
EPS
$1.9
Free cash flow per share
-$1.48
Book value per share
$2.98
Revenue per share
$2.26
TBVPS
$7.22
Balance sheet
Total assets
$450.43M
Total liabilities
$265.04M
Debt
$180.74M
Equity
$185.4M
Working capital
$45.02M
Liquidity
Debt to equity
0.97
Current ratio
1.52
Quick ratio
0.86
Net debt/EBITDA
10.68
Margins
EBITDA margin
8%
Gross margin
21.4%
Net margin
82.8%
Operating margin
2.7%
Efficiency
Return on assets
26.3%
Return on equity
64.7%
Return on invested capital
1%
Return on capital employed
1.2%
Return on sales
3.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CDMO stock price

How has the Avid Bioservices stock price performed over time
Intraday
-2.14%
1 week
27.6%
1 month
7.55%
1 year
-17.21%
YTD
29.27%
QTD
29.27%

Financial performance

How have Avid Bioservices's revenue and profit performed over time
Revenue
$140.69M
Gross profit
$30.07M
Operating income
$3.84M
Net income
$116.47M
Gross margin
21.4%
Net margin
82.8%
The operating margin has dropped by 82% year-on-year and by 18% since the previous quarter
The operating income has plunged by 78% YoY and by 13% from the previous quarter
Avid Bioservices's gross margin has decreased by 34% YoY and by 2.3% from the previous quarter
CDMO's revenue is up by 21% year-on-year and by 4.9% since the previous quarter

Growth

What is Avid Bioservices's growth rate over time

Valuation

What is Avid Bioservices stock price valuation
P/E
9.37
P/B
5.98
P/S
7.89
EV/EBIT
271.88
EV/EBITDA
109.34
EV/Sales
8.77
CDMO's price to earnings (P/E) is 13% higher than its last 4 quarters average of 8.3
CDMO's price to book (P/B) is 44% less than its 5-year quarterly average of 10.6 but 4.9% more than its last 4 quarters average of 5.7
Avid Bioservices's equity has increased by 2.3% QoQ
CDMO's revenue is up by 21% year-on-year and by 4.9% since the previous quarter
CDMO's P/S is 2.6% below its 5-year quarterly average of 8.1

Efficiency

How efficient is Avid Bioservices business performance
Avid Bioservices's return on invested capital has shrunk by 87% YoY and by 9% QoQ
The company's return on sales has shrunk by 79% YoY
CDMO's return on equity is down by 19% since the previous quarter
The return on assets has declined by 9% since the previous quarter

Dividends

What is CDMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CDMO.

Financial health

How did Avid Bioservices financials performed over time
The total assets is 70% greater than the total liabilities
Avid Bioservices's quick ratio has plunged by 63% YoY and by 28% from the previous quarter
The total assets is up by 43% year-on-year
The company's debt is 2.5% lower than its equity
The debt to equity has plunged by 70% YoY and by 3% from the previous quarter
Avid Bioservices's equity has increased by 2.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.